Get started
Award

17H05699

Funded outputs count: 23
Funder award ID: 17H05699
OpenAlex ID: G6263344012
Dysregulation of stress granule dynamics by DCTN1 deficiency exacerbates TDP-43 pathology in Drosophila models of ALS/FTD
2024 · Tetsuhiro Ueda, Toshihide Takeuchi, et al. · Acta Neuropathologica Communications · 14
PDF
FUS regulates RAN translation through modulating the G-quadruplex structure of GGGGCC repeat RNA in C9orf72-linked ALS/FTD
2023 · Yuzo Fujino, Morio Ueyama, et al. · eLife · 20
PDF
Repeat-associated non-AUG translation in neuromuscular diseases: mechanisms and therapeutic insights
2023 · Yuzo Fujino, Kohji Mori, et al. · The Journal of Biochemistry · 9
PDF
Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice
2023 · Toshihide Takeuchi, Kazuhiro Maeta, et al. · Molecular Therapy — Nucleic Acids · 33
Emerging roles of extracellular vesicles in polyglutamine diseases: Mutant protein transmission, therapeutic potential, and diagnostics
2022 · Toshihide Takeuchi, Yoshitaka Nagai · Neurochemistry International · 11
Roles of α-Synuclein and Disease-Associated Factors in Drosophila Models of Parkinson’s Disease
2022 · Mari Suzuki, Kazunori Sango, et al. · International Journal of Molecular Sciences · 20
PDF
ALS-linked FUS mutations dysregulate G-quadruplex-dependent liquid–liquid phase separation and liquid-to-solid transition
2021 · Akira Ishiguro, Jun Lu, et al. · Journal of Biological Chemistry · 64
Insight Into Spinocerebellar Ataxia Type 31 (SCA31) From Drosophila Model
2021 · Taro Ishiguro, Yoshitaka Nagai, et al. · Frontiers in Neuroscience · 17
PDF
Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases
2021 · Eiko N. Minakawa, Yoshitaka Nagai · Frontiers in Neuroscience · 49
PDF
Small molecule targeting r(UGGAA)n disrupts RNA foci and alleviates disease phenotype in Drosophila model
2021 · Tomonori Shibata, Konami Nagano, et al. · Nature Communications · 61
PDF
Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation
2020 · Eiko N Minakawa, Helena Akiko Popiel, et al. · Brain · 36
PDF
Structurally Distinct α‐Synuclein Fibrils Induce Robust Parkinsonian Pathology
2019 · Hideki Hayakawa, Rie Nakatani, et al. · Movement Disorders · 36
Molecular Mechanisms and Future Therapeutics for Spinocerebellar Ataxia Type 31 (SCA31)
2019 · Kinya Ishikawa, Yoshitaka Nagai · Neurotherapeutics · 22
PDF
The lncRNA hsrω regulates arginine dimethylation of human FUS to cause its proteasomal degradation in Drosophila
2019 · Luca Lo Piccolo, Hideki Mochizuki, et al. · Journal of Cell Science · 28
Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
2019 · Kensuke Ikenaka, Mari Suzuki, et al. · Frontiers in Neuroscience · 20
PDF
Arylsulfatase A, a genetic modifier of Parkinson’s disease, is an α-synuclein chaperone
2019 · Jun Sung Lee, Kazuaki Kanai, et al. · Brain · 70
E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease
2019 · Ryusuke Sakai, Mari Suzuki, et al. · PLoS ONE · 14
PDF
Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid
2019 · Keita Kakuda, Kensuke Ikenaka, et al. · Scientific Reports · 43
PDF
Sleep Disturbance as a Potential Modifiable Risk Factor for Alzheimer’s Disease
2019 · Eiko N. Minakawa, Keiji Wada, et al. · International Journal of Molecular Sciences · 123
PDF
Hippo, Drosophila MST, is a novel modifier of motor neuron degeneration induced by knockdown of Caz, Drosophila FUS
2018 · Yumiko Azuma, Takahiko Tokuda, et al. · Experimental Cell Research · 18
NPM-hMLF1 fusion protein suppresses defects of a Drosophila FTLD model expressing the human FUS gene
2018 · Itaru Yamamoto, Yumiko Azuma, et al. · Scientific Reports · 6
PDF
Supplemental Treatment for Huntington’s Disease with miR-132 that Is Deficient in Huntington’s Disease Brain
2018 · Masashi Fukuoka, Masaki Takahashi, et al. · Molecular Therapy — Nucleic Acids · 58
PDF
Developing biomarkers for neurodegenerative diseases using genetically-modified common marmoset models
2018 · Ikuo Tomioka, Yoshitaka Nagai, et al. · Neural Regeneration Research · 6
Year
Topic